Small Molecule Drug Conjugate (SMDC & ALDC)
First-in-class, Precision Guided Cancer Therapy, could replace the original drug and suitable to combine with immunotherapy.
| Drug Name | Payload/MOA/Target | Indication | Rights | Development Stage | ||||
|---|---|---|---|---|---|---|---|---|
| Pre-clinical | IND | Phase I | Phase II | Phase III | ||||
| Drug Name | Payload/MOA/Target | Indication | Rights | Pre-clinical | IND | Phase I | Phase II | Phase III |
Tumor MicroEnvironment Activated Small Molecule Drug Conjugates (TMEA-ALDC & TMEA-SMDC)
| Drug Name | Payload/MOA/Target | Indication | Rights | Pre-clinical | IND | Phase I | Phase II | Phase III |
|
QHL-108 (Legubicin) |
Doxorubicin | Soft Tissue Sarcoma | Global | |||||
|---|---|---|---|---|---|---|---|---|
| Lung Adenocarcinoma | Global | |||||||
| Ovarian Cancer | Global |
|
QHL-236 (Legutaxel) |
Paclitaxel | Solid Tumor | Global | |||||
|---|---|---|---|---|---|---|---|---|
| Bladder Cancer | Global |
| QHL-1618 | DXd | Solid Tumor | Ex-Greater China |
|---|
| QHL-1231 | AXL/VEGF/cMET Multikinase Inhibitor | Solid Tumor | Global |
|---|
| QHL-1031 | TLR7/8 Agonist | Solid Tumor | Global |
|---|
| QHL-1306 | TLR7/8-DXd | Solid Tumor | Global |
|---|
| QHL-1848 | Eribulin | Solid Tumor | Global |
|---|
| QHL-1726 | PAN-RASi | Solid Tumor | Global |
|---|
| QHL-1735 | PAN-RASi-DXd | Solid Tumor | Global |
|---|
| QHL-1207 | DOX-TLR7/8 | Solid Tumor | Global |
|---|
| QHL-506 | PARPi | Solid Tumor | Global |
|---|
| QHL-339 | Platinum | Solid Tumor | Global |
|---|
Registrational Clinical Trial
Biologics Conjugate
Best-In-Class Biologics including conjugate cytokines, antibodies, fusion proteins, and ADCs to create new generation drugs.
| Drug Name | Payload/MOA/Target | Indication | Rights | Development Stage | ||||
|---|---|---|---|---|---|---|---|---|
| Pre-clinical | IND | Phase I | Phase II | Phase III | ||||
| Drug Name | Payload/MOA/Target | Indication | Rights | Pre-clinical | IND | Phase I | Phase II | Phase III |
Partners
| Product (Partners) | Molecule | Rights | Development Stage | ||||
|---|---|---|---|---|---|---|---|
| Pre-clinical | IND | Phase I | Phase II | Phase III | |||
| Product (Partners) | Molecule | Rights | Pre-clinical | IND | Phase I | Phase II | Phase III |
| Product (Partners) | Molecule | Rights | Pre-clinical | IND | Phase I | Phase II | Phase III |
|
I-MAB
|
Confidential | Global |
Confidential
|
|---|
|
Anglikang Pharmaceutical
|
QHL-1618 TMEA-DXd | Greater China |
|---|
|
Partner |
TMEAbody Platform | Global |
|---|
|
Partner |
TMEA-SMDC Platform | Global |
|---|
* Partners and collaborative details are not fully disclosed due to commercial sensitivity
